Die Kosten einer supportiven Therapie mit den Granulozyten-koloniestimulierenden Faktoren (G-CSF) Lenograstim oder Filgrastim bei Patienten mit Chemotherapie-induzierter Neutropenie

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Gesundheitsökonomie & Qualitätsmanagement

• Publication date

  2002-08-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1055/s-2002-33730
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Granulocyte colony stimulating factors: How different are they? How to make a decision?

  2001cited by this paper
• Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia

  2001cited by this paper
• G‐CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial

  1997cited by this paper
• G‐CSF for the prophylaxis of neutropenic fever in patients with small cell lung cancer receiving myelosuppressive antineoplastic chemotherapy: meta‐analysis and pharmacoeconomic evaluation

  1996cited by this paper
• Lenograstim

  1995cited by this paper
• Chemotherapy dose intensity facilitated by use of lenograstim--implications for quality of life and survival.

  1994cited by this paper
• Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor.

  1994cited by this paper
• Measuring the Social Benefits of Medicine

  1983cited by this paper
• Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia.

  1966cited by this paper

• No citing papers are available for this paper.